NLS VPAC1

Drug Profile

NLS VPAC1

Alternative Names: 64Cu-TP-3805; Cu64-NLS-VPAC1; Cu64-TP 3805; Ga68-NLS-VPAC1; NLS-VPAC1; TP3805

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thomas Jefferson University
  • Developer National Institutes of Health (USA); Naviscan PET Systems; NuView Life Sciences; Thomas Jefferson University
  • Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Urogenital cancer
  • No development reported Breast cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(Diagnosis) in USA (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer(Diagnosis) in USA (IV, Injection)
  • 15 Dec 2016 Thomas Jefferson University and the National Institutes of Health initiate a phase I trial for Prostate cancer (Diagnosis) in USA (IV) (NCT02989623)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top